Dialysis Modalities for the Treatment of End-Stage Kidney Disease: A Health Technology Assessment [Internet]
- PMID: 30325617
- Bookshelf ID: NBK531991
Dialysis Modalities for the Treatment of End-Stage Kidney Disease: A Health Technology Assessment [Internet]
Excerpt
The aim of this health technology assessment (HTA) is to inform policy questions regarding the optimal treatment for eligible patients and effective methods of implementation support for the various dialysis options reviewed through an assessment of the clinical effectiveness, cost-effectiveness, patient experiences and perspectives, ethical issues, and implementation issues of dialysis modalities for the treatment of end-stage kidney disease (ESKD).
Copyright © 2017 Canadian Agency for Drugs and Technologies in Health.
Conflict of interest statement
Dr. Michael Copland has received funding from NxStage Medical Inc. for travel, educational lectures and writing articles/editorials, and from Baxter Health Care (Global) for travel. No other conflicts were declared.
Sections
- Reviewers
- Acknowledgements
- Abbreviations
- Protocol Amendments
- Executive Summary
- Introduction
- Policy Questions
- Analytic Framework
- Objectives
- Clinical Review
- Economic Evaluation
- Patient Perspectives and Experiences Review
- Ethical Issues
- Implementation Issues
- Discussion
- Conclusions
- References
- Appendix 1. Analytical Framework
- Appendix 2. Literature Search Strategy
- Appendix 3. List of Included Studies — Clinical Review
- Appendix 4. Study Selection Flow Diagram — Clinical Review
- Appendix 5. Full-Text Screening Checklist — Clinical Review
- Appendix 6. Data Extraction Form — Clinical Review
- Appendix 7. Study and Patient Characteristics — Clinical Review
- Appendix 8. Detailed Outcome Data — Clinical Review
- Appendix 9. Critical Appraisal — Clinical Review
- Appendix 10. Validity of Outcomes for Health-Related Quality of Life Instruments — Clinical Review
- Appendix 11. List of Studies Excluded and the Reasons for Exclusion — Clinical Review
- Appendix 12. Modelling Mortality — Economic Review
- Appendix 13. Clinical Inputs on Relative Efficacy and Safety Estimates, Applied in Scenario Analyses
- Appendix 14. Subcategories of Costs by Study (2015 CAN $) — Economic Review
- Appendix 15. Additional Costs Inputs in the Economic Review
- Appendix 16. Sensitivity Analyses — Varying Discount Rates, Time Horizon, and Older Age (All Modalities)
- Appendix 17. Scenario Analyses — Prevalent Patients (all modalities)
- Appendix 18. Reference Case Results, All Dialysis Modalities
- Appendix 19. Findings From Sensitivity Analyses, PD Versus Conventional ICHD
- Appendix 20. Findings From Sensitivity Analyses — Home HD Versus Cv ICHD
- Appendix 21. Findings from Sensitivity Analyses — HHD Versus PD
- Appendix 22. Findings from Additional Sensitivity Analyses
- Appendix 23. Quality Assessment Instrument — Patient Preferences Review
- Appendix 24. Study Selection Flow Diagram — Patient Preferences Review
- Appendix 25. List of Included Studies — Patient Preferences Review
- Appendix 26. List of Excluded Studies — Patient Preferences Review
- Appendix 27. Characteristics of Included Studies — Patient Preferences Review
- Appendix 28. Quality Assessment of Included Studies — Patient Preferences Review
- Appendix 29. Implementation Surveys — Implementation Review
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
